Liquidia Corp. (LQDA)
70.28
+1.66
(+2.41%)
USD |
NASDAQ |
Aug 24, 16:00
70.28
0.00 (0.00%)
After-Hours: 20:00
Liquidia Enterprise Value : 6.013B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 6.013B |
| August 20, 2026 | 6.229B |
| August 19, 2026 | 6.611B |
| August 18, 2026 | 6.521B |
| August 17, 2026 | 6.822B |
| August 14, 2026 | 6.531B |
| August 13, 2026 | 6.323B |
| August 12, 2026 | 6.919B |
| August 11, 2026 | 7.744B |
| August 10, 2026 | 8.009B |
| August 07, 2026 | 7.937B |
| August 06, 2026 | 7.866B |
| August 05, 2026 | 7.839B |
| August 04, 2026 | 7.773B |
| August 03, 2026 | 7.370B |
| July 31, 2026 | 7.393B |
| July 30, 2026 | 7.633B |
| July 29, 2026 | 7.634B |
| July 28, 2026 | 7.634B |
| July 27, 2026 | 7.420B |
| July 24, 2026 | 7.581B |
| July 23, 2026 | 7.831B |
| July 22, 2026 | 7.654B |
| July 21, 2026 | 7.106B |
| July 20, 2026 | 6.767B |
| Date | Value |
|---|---|
| July 17, 2026 | 7.021B |
| July 16, 2026 | 6.605B |
| July 15, 2026 | 6.826B |
| July 14, 2026 | 6.714B |
| July 13, 2026 | 6.243B |
| July 10, 2026 | 6.842B |
| July 09, 2026 | 7.156B |
| July 08, 2026 | 6.979B |
| July 07, 2026 | 7.136B |
| July 06, 2026 | 6.956B |
| July 02, 2026 | 6.931B |
| July 01, 2026 | 6.966B |
| June 30, 2026 | 7.003B |
| June 29, 2026 | 6.596B |
| June 26, 2026 | 6.865B |
| June 25, 2026 | 6.755B |
| June 24, 2026 | 6.633B |
| June 23, 2026 | 6.500B |
| June 22, 2026 | 6.628B |
| June 18, 2026 | 6.238B |
| June 17, 2026 | 6.024B |
| June 16, 2026 | 5.968B |
| June 15, 2026 | 6.303B |
| June 12, 2026 | 6.252B |
| June 11, 2026 | 6.287B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Indivior Pharmaceuticals, Inc. | 4.638B |
| Harmony Biosciences Holdings, Inc. | 1.770B |
| Johnson & Johnson | 679.08B |
| Amneal Pharmaceuticals, Inc. | 8.459B |
| Corcept Therapeutics, Inc. | 12.89B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 74.72M |
| Revenue (Quarterly) | 171.68M |
| Total Expenses (Quarterly) | 96.96M |
| EPS Diluted (Quarterly) | 0.7369 |
| Gross Profit Margin (Quarterly) | 93.10% |
| Profit Margin (Quarterly) | 43.52% |
| Earnings Yield | 1.94% |
| Operating Earnings Yield | 2.47% |
| Normalized Earnings Yield | 1.941 |